Advanced Filters
noise

Found 706 clinical trials

UPCC 02419: An Open-label Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285) A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Patients with Advanced Systemic Mastocytosis

This research study is an open-label study designed to learn about the safety and effectiveness of an experimental drug called avapritinib (also known as BLU-285) when given to individuals who have been diagnosed with ASM, SM-AHN, or MCL. Experimental means that it is not yet known if this drug helps …

99 years and younger
All
Phase 2

Opioid Taper in Chronic Pain

Are you and your physician planning to taper your opioid dose? If so, you may be eligible to participate in a paid research study looking to evaluate how the perception of pain changes as opioid medication is tapered. To learn more about this study contact research coordinator Lizette at 215-615-0512 or …

21-70 years
All
Phase N/A

Psoriasis Specimen BioBank

The last 2 decades have witnessed a dramatic expansion in our understanding of the genetics, pathophysiology, and comorbidities of psoriasis leading to the development and approval of a variety of treatment strategies targeting pathways such as JAK/STAT, PDE4, TNF, IL12/23, and IL-17. We propose creating a biobank of specimens from …

18-99 years
All

A Phase 3 Randomized Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (Cadenza)

This is a randomized, double-blind, placebo-controlled, multicenter study in patients with primary cold agglutinin disease (CAgD) without a recent history of blood transfusion. Eligible patients will receive study drug (BIVV009 or placebo) and undergo safety and efficacy assessments for 6 months (26 weeks) during Part A. Following completion of the …

99 years and younger
All
Phase 3

UPCC 06419: Phase 1/2 Open Label Multi-center Dose-Escalation Study to Assess the Safety Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907) a PI3K and HDAC Inhibitor in Subjects with Relapsed and/or Refractory Lymphoma

This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.

99 years and younger
All
Phase 1

A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

The trial will enroll subjects who have had an inadequate response (IR) to prior biologic therapy (bio-IR). The bio-IR population is defined as subjects with documented intolerance or inadequate response to one or more of the approved biologics for UC (infliximab, adalimumab, golimumab, and/or vedolizumab).

99 years and younger
All
Phase 3

A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis

A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and compensated cirrhosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …

99 years and younger
All
Phase 2

A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and F3 fibrosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection. There is also a follow-up period to assess long-term bone mineral density and immunogenicity. Target population …

99 years and younger
All
Phase 2

mPeer2Peer

The purpose of this study is to develop and test the utility of a smartphone program, mPhenomic, that facilitates peer recruitment via SMS text messages and assess how different behavioral incentives affect this system. Outcomes are measured by the number of referrals that participants, called seeds, make to people, named …

99 years and younger
All

Simplify language using AI